What is Bacopa monnieri? A plain-English guide
Bacopa monnieri is a plant used in Ayurveda, a traditional system of medicine. In trials that lasted about 12 weeks, bacopa did better than a dummy pill on some memory tests, but not on all of them. Single doses gave mixed results. Stomach and gut problems were the most common side effects.
By the NootropicsWork Editorial Team. A plain-English guide, 5 minute read.
Bottom line
Bacopa monnieri is a plant used in Ayurveda, a traditional system of medicine. In trials that lasted about 12 weeks, bacopa did better than a dummy pill on some memory tests, but not on all of them. Single doses gave mixed results. Stomach and gut problems were the most common side effects.
- A review of six 12-week trials found bacopa beat a placebo on 9 of 17 recall tests in adults without serious memory problems [1].
- But a 12-week trial in 72 healthy adults, supported by Hindustan Unilever, found no clear difference from a dummy pill on any thinking test [4].
- Stomach and gut problems, such as nausea, cramps and more frequent stools, were the main side effects reported in trials [3][8].
For every study, dose and grade, read our full research summary on Bacopa monnieri.
What is Bacopa monnieri?
Bacopa monnieri is a plant that is also called Brahmi or Waterhyssop [8].
Studies tested extracts, which are concentrated forms of the plant [1].
What do people use Bacopa monnieri for?
Ayurveda uses bacopa for memory [8]. A few small studies tested whether one dose does anything within 2 hours [6][7].
What does the research show?
Does bacopa help with memory?
Evidence grade for delayed recall: B, moderate. Why this grade
A systematic review is a study that gathers all the trials on one question and sums them up. One such review looked at six randomized controlled trials [1]. In this kind of trial, people are split by chance into groups, and one group gets a placebo, a dummy pill.
All six lasted 12 weeks and studied adults without serious memory or thinking problems [1]. Compared with a placebo, bacopa improved 9 of 17 tests of free recall, which means remembering a list without hints [1]. There was little sign of benefit in other areas of thinking [1].
A larger 2026 review pooled 29 trials of bacopa or another herb, ginkgo, with 2,107 healthy adults [2]. It was a network meta-analysis, which compares treatments both directly and across different trials. For delayed memory, low doses of bacopa did better than a placebo [2]. The authors say the lack of direct comparisons may limit the strength of this evidence [2].
Single trials point both ways. In 98 healthy adults over 55, a branded extract called BacoMind improved learning and delayed recall on a word-list test, compared with a placebo [3]. Of the 98, 81 finished [3]. But in 72 healthy adults aged 35 to 60, there was no clear difference on any thinking test, in a trial supported by Hindustan Unilever [4]. Three of its authors worked for Unilever, and a Unilever company sells products that contain Brahmi [4].
A third trial, funded by US Pharma Lab, studied 101 adults aged 40 to 70 with self-reported memory and attention problems [5]. Its lead author runs a research company that has received funding from supplement companies [5]. Among the 87 people who finished, it found no difference on any of its main tests: word-list learning, attention and working memory [5].
In all three of these trials, neither the volunteers nor the researchers knew who got bacopa [3][4][5]. So evidence is mixed. The trials lasted about 12 weeks, so they do not show what happens with longer use [1].
Does one dose of bacopa do anything?
Evidence grade for acute cognitive performance: C, limited. Why this grade
The single-dose studies are small, and their results disagree [6][7]. In 38 healthy adults, 300 mg of bacopa made no clear difference on any test 2 hours later, compared with a placebo [6]. In a study of 17 healthy adults, each person took every treatment in turn [7]. Doses of 320 mg and 640 mg improved scores on two tasks 1 and 2 hours later [7].
Both studies came from researchers at the same university [6][7]. The authors of the second study say the results need to be repeated in a larger group [7].
Does bacopa help with stress?
Evidence grade for perceived stress: C, limited. Why this grade
Evidence is mixed. Two 12-week trials, funded by US Pharma Lab and Hindustan Unilever, used questionnaires where people rate their own feelings [4][5]. In the US Pharma Lab trial, people taking bacopa reported larger drops in how strongly they react to stress [5]. This was not the trial's main question, and it counted only the 87 of 101 people who finished [5].
In the Hindustan Unilever trial, there was only a trend toward lower anxiety in the moment [4].
To see what each grade means, read how we grade evidence.
How much did studies use?
Table: Doses used in studies (not a recommendation)
| What was studied | Doses used in studies | Source |
|---|---|---|
| 12-week memory trials (review of six trials) | 300-450 mg extract a day | [1] |
| 12-week trial in healthy adults over 55 | 300 mg a day | [3] |
| 12-week trial in adults aged 35 to 60 (supported by Hindustan Unilever) | 450 mg a day | [4] |
| 12-week trial in adults aged 40 to 70 (funded by US Pharma Lab) | 300 mg a day | [5] |
| Network meta-analysis dose groups | Low: 300 to under 600 mg a day; high: 600 mg a day or more | [2] |
| Single-dose studies | 300 mg; 320 mg and 640 mg | [6][7] |
A 2025 review describes doses in studies as usually 300 to 600 mg a day [8]. The same review says more research is needed to work out doses and make sure of safety [8]. These are amounts used in research, not a recommendation for anyone.
Is Bacopa monnieri safe?
A 2025 review says stomach and gut problems are the most common side effects [8]. In a 12-week trial of BacoMind in healthy adults over 55, bacopa caused more frequent stools, stomach cramps and nausea than a placebo [3]. In the trial funded by US Pharma Lab, people on bacopa reported more side effects than people on a placebo [5]. These were mostly stomach complaints and headaches [5].
A 2023 letter reports a case of necrotizing myopathy, a serious muscle condition, after use of a bacopa supplement [10]. We could not read the letter, so its details are not verified as of November 12, 2026.
In lab tests, bacopa extract reduced the activity of four enzymes: CYP1A2, CYP3A4, CYP2C9 and CYP2C19 [9]. They belong to the cytochrome P450 family, which the body uses to break down many medicines. The authors say this could contribute to herb-drug interactions [9].
The 2025 review also reports an interaction with amitriptyline [8]. It reports back pain and heavy sweating with the antidepressant agomelatine [8]. It also reports a heart attack with the antidepressant moclobemide [8]. The review gives no study details, so these reports do not show that bacopa caused the events. It also advises care with medicines that affect thyroid hormone levels [8].
If you take any of these medicines, talk to your doctor or pharmacist before combining them with bacopa.
Who should be careful with Bacopa monnieri?
- Pregnant and breastfeeding women. A 2025 review notes a lack of research on safe use in this group [8].
- People with an overactive thyroid. The same review advises special caution, based on a study in male mice [8].
- People who take medicines broken down by the CYP enzymes above, given the lab findings [9].
Anyone in these groups should talk with a clinician about bacopa.
Want the full picture?
Read the full research summary for every study, all four graded outcomes, drug interactions and legal status by market.
Grades for the outcomes on this page, from the Bacopa monnieri research summary. They update when the evidence does.
| Outcome | Grade | Basis | Modifiers | Rationale |
|---|---|---|---|---|
| Delayed recall | B Moderate | >=2 RCTs with mostly consistent results (B); A not met because two 12-week RCTs were null and the newest synthesis relies on indirect comparisons | Short-term only | Why B grade for Delayed recall: explainedApproved of the Delayed recall grade |
| Acute cognitive performance | C Limited, no effect found | Only small single-dose RCTs (n = 17-38) with inconsistent results (C); too few and too small for N | Single research group | Why C grade for Acute cognitive performance: explainedApproved of the Acute cognitive performance grade |
| Perceived stress | C Limited | RCT results inconsistent (B not met); positive findings are secondary or trend-level; conservative reading per citation-rules 9 | Subjective outcome only | Why C grade for Perceived stress: explainedApproved of the Perceived stress grade |
References
- Pase MP, Kean J, Sarris J, et al. The cognitive-enhancing effects of Bacopa monnieri: a systematic review of randomized, controlled human clinical trials. J Altern Complement Med. 2012.
- Tiemtad P, Ingkaninan K, Temkitthawon P, et al. Comparative effects of Bacopa monnieri and Ginkgo biloba on cognitive functions: A systematic review and network meta-analysis. Phytomedicine. 2026.
- Morgan A, Stevens J. Does Bacopa monnieri improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trial. J Altern Complement Med. 2010.
- Sathyanarayanan V, Thomas T, Einöther SJ, et al. Brahmi for the better? New findings challenging cognition and anti-anxiety effects of Brahmi (Bacopa monniera) in healthy adults. Psychopharmacology (Berl). 2013.
- Lopresti AL, Smith SJ. The Effects of a Bacopa monnieri Extract (Bacumen®) on Cognition, Stress, and Fatigue in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Trial. Clin Drug Investig. 2025.
- Nathan PJ, Clarke J, Lloyd J, et al. The acute effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy normal subjects. Hum Psychopharmacol. 2001.
- Benson S, Downey LA, Stough C, et al. An acute, double-blind, placebo-controlled cross-over study of 320 mg and 640 mg doses of Bacopa monnieri (CDRI 08) on multitasking stress reactivity and mood. Phytother Res. 2014.
- Gościniak A, Stasiłowicz-Krzemień A, Szeląg M, et al. Bacopa monnieri: Preclinical and Clinical Evidence of Neuroactive Effects, Safety of Use and the Search for Improved Bioavailability. Nutrients. 2025.
- Ramasamy S, Kiew LV, Chung LY. Inhibition of human cytochrome P450 enzymes by Bacopa monnieri standardized extract and constituents. Molecules. 2014.
- Yaworski AM, Blyumin M, Chang T, et al. Necrotizing myopathy with elevated anti-HMGCR antibodies following exposure to the supplement Bacopa. Muscle Nerve. 2023.